Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer
NCT00003257 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39
Last updated 2013-12-04
Summary
RATIONALE: Inserting the gene for p53 into a person's tumor may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have recurrent head and neck cancer.
Conditions
Interventions
- BIOLOGICAL
-
Ad5CMV-p53 gene
Sponsors & Collaborators
-
Aventis Pharmaceuticals
lead INDUSTRY
Principal Investigators
-
Lyndah Dreiling, MD · Aventis Pharmaceuticals
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1998-01-31
Countries
- United States
Study Locations
More Related Trials
-
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
NCT02626000 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
NCT00500760 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02207530 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537 ·Status: RECRUITING ·Phase: PHASE2
-
Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC
NCT05053737 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
NCT00939627 ·Status: COMPLETED ·Phase: PHASE2
-
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
NCT02952586 ·Status: TERMINATED ·Phase: PHASE3
-
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
NCT03422536 ·Status: COMPLETED ·Phase: PHASE2
-
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00513435 ·Status: COMPLETED ·Phase: PHASE2
-
Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer
NCT02079324 ·Status: COMPLETED ·Phase: PHASE1
-
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
NCT02551159 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer
NCT02262741 ·Status: COMPLETED ·Phase: PHASE1
-
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck
NCT00003182 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
NCT07059221 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT05063552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
NCT06719479 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
NCT00458978 ·Status: COMPLETED ·Phase: PHASE2
-
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05721755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
NCT00798655 ·Status: COMPLETED ·Phase: PHASE2
-
Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
NCT00006224 ·Status: TERMINATED ·Phase: PHASE2
-
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
NCT07156227 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
NCT02538510 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
NCT06005324 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Sorafenib/Cetuximab in Head and Neck Cancer
NCT00815295 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
NCT00022217 ·Status: UNKNOWN ·Phase: PHASE2